Analysis of Pros and Cons in Using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007: Production, Costs, and PET/CT Applications in Patients with Prostate Cancer
Authors:
- Costantina MaistoCMCostantina Maisto
- Michela AurilioMAMichela Aurilio
- Anna MoriscoAMAnna Morisco
- Roberta de MarinoRMRoberta de Marino
- Monica Josefa Buonanno RecchimuzzoMRMonica Josefa Buonanno Recchimuzzo
- Luciano CarideoLCLuciano Carideo
- Laura D’ambrosioLDLaura D’ambrosio
- Francesca Di GennaroFGFrancesca Di Gennaro
- Aureliana EspositoAEAureliana Esposito
- Paolo GaballoPGPaolo Gaballo
- Valentina Pirozzi PalmeseVPValentina Pirozzi Palmese
- Valentina PorfidiaVPValentina Porfidia
Open Access
Abstract
The aim of this work is to compare [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 PET/CT as imaging agents in patients with prostate cancer (PCa). Comparisons were made by evaluating times and costs of the radiolabeling process, imaging features including pharmacokinetics, and impact on patient management. The analysis of advantages and drawbacks of both radioligands might help to make a better choice based on firm data. For [68Ga]Ga-PSMA-11, the radiochemical yield (RCY) using a low starting activity (L, average activity of 596.55 ± 37.97 MBq) was of 80.98 ± 0.05%, while using a high one (H, average activity of 1436.27 ± 68.68 MBq), the RCY was 71.48 ± 0.04%. Thus, increased starting activities of [68Ga]-chloride negatively influenced the RCY. A similar scenario occurred for [18F]PSMA-1007. The rate of detection of PCa lesions by Positron Emission Tomography/Computed Tomography (PET/CT) was similar for both radioligands, while their distribution in normal organs significantly differed. Furthermore, similar patterns of biodistribution were found among [18F]PSMA-1007, [68Ga]Ga-PSMA-11, and [177Lu]Lu-PSMA-617, the most used agent for RLT. Moreover, the analysis of economical aspects for each single batch of production corrected for the number of allowed PET/CT examinations suggested major advantages of [18F]PSMA-1007 compared with [68Ga]Ga-PSMA-11. Data from this study should support the proper choice in the selection of the PSMA PET radioligand to use on the basis of the cases to study.Keywords
This publication has 20 references indexed in Scilit:
- Fluorine-18 labelled prostate-specific membrane antigen (PSMA)-1007 positron-emission tomography–computed tomography: normal patterns, pearls, and pitfallsClinical Radiology, 2020
- Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2020
- Rapid and automated production of [68Ga]gallium chloride and [68Ga]Ga-DOTA-TATE on a medical cyclotronNuclear Medicine and Biology, 2019
- Men with a susceptibility to prostate cancer and the role of genetic based screeningTranslational Andrology and Urology, 2018
- Continuation of comprehensive quality control of the itG 68 Ge/ 68 Ga generator and production of 68 Ga-DOTATOC and 68 Ga-PSMA-HBED-CC for clinical research studiesNuclear Medicine and Biology, 2017
- 177Lu-PSMA Radioligand Therapy for Prostate CancerJournal of Nuclear Medicine, 2017
- 44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617EJNMMI Research, 2017
- Physics of pure and non-pure positron emitters for PET: a review and a discussionEJNMMI Physics, 2016
- Comprehensive Quality Control of the ITG 68Ge/68Ga Generator and Synthesis of 68Ga-DOTATOC and 68Ga-PSMA-HBED-CC for Clinical ImagingJournal of Nuclear Medicine, 2016
- Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomographyApplied Radiation and Isotopes, 2013